Medication info
Budian Tablets 10 mg (Empagliflozin)

Budian Tablets 10 mg (Empagliflozin)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›10mg / 1 tablet
Manufacturer / importer
Bukwang Pharmaceutical Co., Ltd.
Appearance
Light yellow round film-coated tablets
Packaging
PTP - 30 tablets/PTP [10 tablets/PTP x 3]
Approval status
Active

MFDS item code 202105537 · Approved 2021.07.23 · Insurance code 642204840

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The recommended dose of this medicine is 10 mg once daily, both as monotherapy and as add-on combination therapy with other glucose-lowering agents, such as insulin. If 10 mg of this medicine is well tolerated but additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take a double dose on the same day. No dose adjustment is necessary in patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) below 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well but have a persistently reduced glomerular filtration rate below 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose should be adjusted to or maintained at 10 mg once daily. This medicine should be discontinued if the glomerular filtration rate decreases to below 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this medicine in patients with end-stage renal disease (ESRD) or those on dialysis, as efficacy is not expected. No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment because it has not been studied in this population. No dose adjustment is necessary based on age. Renal function and the risk of volume depletion should be considered in patients 75 years of age or older. Initiation of treatment with this medicine is not recommended in patients 85 years of age or older because clinical experience is limited.

Ingredients

Manufacturer
Bukwang Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes with poor blood sugar control
  • cardiovascular diseases
View approved original text

This medication is used to support blood sugar control in adult patients with type 2 diabetes, complementing dietary and exercise regimens. It can be used alone or in combination with other medications. In particular, it should be administered based on professional guidance if cardiovascular diseases are confirmed in patients whose blood sugar control is insufficient. This drug is expected to have positive effects on blood sugar management and reduction of cardiovascular risk.

How to take

Adult dose

The recommended dose of this medicine is 10 mg once daily, both as monotherapy and as add-on combination therapy with other glucose-lowering agents, such as insulin. If 10 mg of this medicine is well tolerated but additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take a double dose on the same day. No dose adjustment is necessary in patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) below 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well but have a persistently reduced glomerular filtration rate below 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose should be adjusted to or maintained at 10 mg once daily. This medicine should be discontinued if the glomerular filtration rate decreases to below 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this medicine in patients with end-stage renal disease (ESRD) or those on dialysis, as efficacy is not expected. No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment because it has not been studied in this population. No dose adjustment is necessary based on age. Renal function and the risk of volume depletion should be considered in patients 75 years of age or older. Initiation of treatment with this medicine is not recommended in patients 85 years of age or older because clinical experience is limited.

Precautions

This drug should not be used in patients with hypersensitivity to the active ingredient or any of the components. It should not be given to patients with type 1 diabetes or diabetic ketoacidosis. It should not be used in patients with severely impaired renal function, specifically those with a glomerular filtration rate below 30 mL/min/1.73m2, end-stage renal disease, or those undergoing dialysis. This drug contains lactose and should not be administered to patients with galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption syndromes. In patients with renal impairment, it should be used cautiously, and treatment should be avoided in those with a glomerular filtration rate below 60 mL/min/1.73m². If there is continued decline in renal function during treatment, dose adjustment or discontinuation may be necessary. Experience with this medication is limited in patients with heart failure, particularly those with severe heart failure, so it should be used cautiously and is not recommended in severe cases. When used in conjunction with insulin or sulfonylureas, the risk of hypoglycemia may increase, necessitating dose adjustments of these medications. While using this medication, monitoring for adverse reactions such as hypoglycemia, infections, particularly genital and urinary tract infections, increased urination, decreased fluid volume, is important. Serious metabolic abnormalities known as ketoacidosis may occur, thus if related symptoms (nausea, vomiting, abdominal pain, dyspnea, etc.) arise, consult with a healthcare professional immediately. In elderly patients, particularly those over 75 years of age, there is an increased risk of fluid volume loss, and caution is advised. Severe urinary infections such as urosepsis and pyelonephritis have been reported, and rapid evaluation and treatment are necessary if infection symptoms are present. There is an increased risk of genital fungal infections, and appropriate treatment is necessary if related symptoms occur. While taking this medication, a positive urine glucose test may occur. Caution is required when driving or operating machinery due to the risk of hypoglycemia. Administration of this drug during pregnancy is not recommended, and it should be discontinued if pregnancy is confirmed. For nursing mothers, since this drug may be excreted in breast milk, cessation of breastfeeding is advisable. Safety and effectiveness in children under 18 have not been established, and therefore it should not be used in this age group. No specific toxic symptoms have been reported in the event of overdose; however, appropriate treatment based on the clinical condition is needed. This drug should be kept out of reach of children, and transferring it to another container is not advisable as it may affect quality.

Side effects

  • Hypoglycemia
  • vulvovaginitis
  • balanitis
  • and other genital infections
  • urinary tract infection
  • perineal necrosis
  • ketoacidosis
  • pruritus
  • rash
  • urticaria
Show 12 more
  • angioedema
  • decreased fluid volume
  • increased urination
  • urination difficulty
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • increased hematocrit
  • urosepsis
  • pyelonephritis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. Additionally, it is safest to store the medication at room temperature between 1°C and 30°C, avoiding extremely hot or cold environments.

Appearance and packaging

Appearance

Light yellow round film-coated tablets

Package unit

PTP - 30 tablets/PTP [10 tablets/PTP x 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.